Outcome After Coronary Artery Bypass Grafting (E-CABG)
E-CABG: European Multicenter Study on the Outcome After Coronary Artery Bypass Grafting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fausto Biancari, Professor
- Phone Number: +358407333973
- Email: faustobiancari@yahoo.it
Study Locations
-
-
-
Oulu, Finland
- Recruiting
- Oulu University Hospital
-
Contact:
- Fausto Biancari, Professor
- Phone Number: +358407333973
- Email: faustobiancari@yahoo.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of aged > 18 years undergoing isolated CABG for stable coronary artery disease or acute coronary syndrome. Patients undergoing Maze procedure will be included in this registry.
Exclusion Criteria:
- Patients undergoing any other major cardiac surgery procedure will be excluded from this registry.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Coronary artery bypass surgery
Patients undergoing coronary artery bypass surgery.
|
Patients will undergo coronary artery bypass grafting
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: The outcome measure will be assessed at time points up to 10 years after surgery
|
Any death occurring after surgery
|
The outcome measure will be assessed at time points up to 10 years after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra-aortic balloon pump
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Use of intra-aortic balloon pump for acute heart failure after surgery
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Resternotomy for bleeding
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Re-exploration for excessive bleeding
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Stroke
Time Frame: The outcome measure will be assessed at time points up to 10 years after surgery
|
Any ischemic brain injury occurring after surgery and lasting > 24 hours
|
The outcome measure will be assessed at time points up to 10 years after surgery
|
|
Prolonged use of inotropes
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Use of inotropes > 12 hours after surgery
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
ECMO
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Use of extracorporeal membrane oxygenation for acute heart failure after surgery
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Repeat revascularization
Time Frame: The outcome measure will be assessed at time points up to 10 years after surgery
|
Any repeat myocardial revascularization procedure performed after surgery
|
The outcome measure will be assessed at time points up to 10 years after surgery
|
|
Wound infection
Time Frame: Participants will be followed up for 3 months after surgery
|
Any deep sternal or lower limb wound infection occurring after surgery
|
Participants will be followed up for 3 months after surgery
|
|
Blood losses
Time Frame: Participants will be followed 12 hours after surgery
|
Amont of blood losses from drainages 12 hours after surgery
|
Participants will be followed 12 hours after surgery
|
|
Nadir hematocrit
Time Frame: Participants will be followed during the operation day
|
Lowest hematocrit level during the operation day
|
Participants will be followed during the operation day
|
|
Use of blood products
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Use of any blood product (red blood cell, fresh frozen plasma, Octaplas, platelets) during the in-hospital stay
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Use of prothrombotic drugs
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Perioperative use of cryoprecipitate, PCC and/or rFVIIa for excessive bleeding PCCs Perioperative use of rFVIIa, PCC, cryoprecipitate |
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Atrial fibrillation
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
New episode of atrial fibrillation requiring or not cardioversion during the in-hospital stay
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Renal replacement therapy
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Any renal replacement therapy during the in-hospital stay
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Highest level of serum creatinine
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Highest level of serum creatinine during the in-hospital stay
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Myocardial infarction
Time Frame: The outcome measure will be assessed at time point up to 10 years after surgery
|
Myocardial infarction (diagnosed by ECG and troponin monitoring) any time after surgery
|
The outcome measure will be assessed at time point up to 10 years after surgery
|
|
Length of stay in the intensive care unit
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Length of stay in the intensive care unit after surgery
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Pericardial effusion
Time Frame: Participants will be followed up to 3 months after surgery.
|
Pericardial effusion requiring medical or surgical treatment
|
Participants will be followed up to 3 months after surgery.
|
|
Postoperative use of antibiotics
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Postoperative use of antibiotics for postoperative infection
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
|
Gastrointestinal complications
Time Frame: Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Any gastrointestinal complication requiring medical or surgical treatment after surgery
|
Participants will be followed for the duration of hospital stay (expected: 10 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Fausto Biancari, Professor, University of Oulu, Oulu, Finland
Publications and helpful links
General Publications
- Rubino AS, Nicolini F, Tauriainen T, Demal T, De Feo M, Onorati F, Faggian G, Bancone C, Perrotti A, Chocron S, Dalen M, Santarpino G, Fischlein T, Maselli D, Musumeci F, Santini F, Salsano A, Zanobini M, Saccocci M, Bounader K, Gatti G, Ruggieri VG, Mignosa C, Juvonen T, Mariscalco G, Biancari F. Failure to achieve a satisfactory cardiac outcome after isolated coronary surgery in low-risk patients. Interact Cardiovasc Thorac Surg. 2020 Jul 1;31(1):9-15. doi: 10.1093/icvts/ivaa062.
- Biancari F, Gatti G, Rosato S, Mariscalco G, Pappalardo A, Onorati F, Faggian G, Salsano A, Santini F, Ruggieri VG, Perrotti A, Santarpino G, Fischlein T, Saccocci M, Musumeci F, Rubino AS, De Feo M, Bancone C, Nicolini F, Kinnunen EM, Demal T, D'Errigo P, Juvonen T, Dalen M, Maselli D. Preoperative risk stratification of deep sternal wound infection after coronary surgery. Infect Control Hosp Epidemiol. 2020 Apr;41(4):444-451. doi: 10.1017/ice.2019.375. Epub 2020 Jan 20.
- Khodabandeh S, Biancari F, Kinnunen EM, Mariscalco G, Airaksinen J, Gherli R, Gatti G, Demal T, Onorati F, Faggian G, De Feo M, Santarpino G, Rubino AS, Maselli D, Salsano A, Nicolini F, Zanobini M, Ruggieri VG, Bounader K, Perrotti A, Dalen M. Perioperative Bleeding in Patients With Acute Coronary Syndrome Treated With Fondaparinux Versus Low-Molecular-Weight Heparin Before Coronary Artery Bypass Grafting. Am J Cardiol. 2019 Feb 15;123(4):565-570. doi: 10.1016/j.amjcard.2018.11.028. Epub 2018 Nov 24.
- Santarpino G, Nicolini F, De Feo M, Dalen M, Fischlein T, Perrotti A, Reichart D, Gatti G, Onorati F, Franzese I, Faggian G, Bancone C, Chocron S, Khodabandeh S, Rubino AS, Maselli D, Nardella S, Gherli R, Salsano A, Zanobini M, Saccocci M, Bounader K, Rosato S, Tauriainen T, Mariscalco G, Airaksinen J, Ruggieri VG, Biancari F. Prognostic Impact of Asymptomatic Carotid Artery Stenosis in Patients Undergoing Coronary Artery Bypass Grafting. Eur J Vasc Endovasc Surg. 2018 Nov;56(5):741-748. doi: 10.1016/j.ejvs.2018.07.042. Epub 2018 Sep 6.
- Reichart D, Rosato S, Nammas W, Onorati F, Dalen M, Castro L, Gherli R, Gatti G, Franzese I, Faggian G, De Feo M, Khodabandeh S, Santarpino G, Rubino AS, Maselli D, Nardella S, Salsano A, Nicolini F, Zanobini M, Saccocci M, Bounader K, Kinnunen EM, Tauriainen T, Airaksinen J, Seccareccia F, Mariscalco G, Ruggieri VG, Perrotti A, Biancari F. Clinical frailty scale and outcome after coronary artery bypass grafting. Eur J Cardiothorac Surg. 2018 Dec 1;54(6):1102-1109. doi: 10.1093/ejcts/ezy222.
- Mariscalco G, Rosato S, Serraino GF, Maselli D, Dalen M, Airaksinen JKE, Reichart D, Zanobini M, Onorati F, De Feo M, Gherli R, Santarpino G, Rubino AS, Gatti G, Nicolini F, Santini F, Perrotti A, Bruno VD, Ruggieri VG, Biancari F. Prior Percutaneous Coronary Intervention and Mortality in Patients Undergoing Surgical Myocardial Revascularization: Results From the E-CABG (European Multicenter Study on Coronary Artery Bypass Grafting) With a Systematic Review and Meta-Analysis. Circ Cardiovasc Interv. 2018 Feb;11(2):e005650. doi: 10.1161/CIRCINTERVENTIONS.117.005650.
- Biancari F, Brascia D, Onorati F, Reichart D, Perrotti A, Ruggieri VG, Santarpino G, Maselli D, Mariscalco G, Gherli R, Rubino AS, De Feo M, Gatti G, Santini F, Dalen M, Saccocci M, Kinnunen EM, Airaksinen JK, D'Errigo P, Rosato S, Nicolini F. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost. 2017 Feb 28;117(3):445-456. doi: 10.1160/TH16-09-0721. Epub 2016 Dec 1.
- Biancari F, Ruggieri VG, Perrotti A, Svenarud P, Dalen M, Onorati F, Faggian G, Santarpino G, Maselli D, Dominici C, Nardella S, Musumeci F, Gherli R, Mariscalco G, Masala N, Rubino AS, Mignosa C, De Feo M, Della Corte A, Bancone C, Chocron S, Gatti G, Gherli T, Kinnunen EM, Juvonen T. European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG registry): Study Protocol for a Prospective Clinical Registry and Proposal of Classification of Postoperative Complications. J Cardiothorac Surg. 2015 Jun 30;10:90. doi: 10.1186/s13019-015-0292-z.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1 (Mobile Health and Wellness Program)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.